Celldex Therapeutics
CLDX
161 hedge funds and large institutions have $1.78B invested in Celldex Therapeutics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 55 reducing their positions, and 26 closing their positions.
137% more call options, than puts
Call options by funds: $19.4M | Put options by funds: $8.18M
1.55% more ownership
Funds ownership: 103.31% → 104.86% (+1.5%)
9% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 55
4% less funds holding
Funds holding: 168 → 161 (-7)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
17% less capital invested
Capital invested by funds: $2.15B → $1.78B (-$367M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$33.6M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$31M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.8M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$18.1M |
| 5 |
Morgan Stanley
New York
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$20.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$14.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$14.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.9M |
| 5 |
SC
Sessa Capital
New York
|
-$9.45M |
CLDX Hedge Fund Activity: Q1 2023 in Review
161 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2023, worth a combined $1.78B — down 17% from $2.15B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CLDX and 22 opened new positions — a net loss of 4 holders — while 55 trimmed existing stakes and 50 added.
The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $33.6M. The largest seller was Wellington Management Group, cutting an estimated $20.1M.
- 161 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2023, down from 168 in Q4 2022.
- Funds reported $1.78B of Celldex Therapeutics stock for Q1 2023, down 17% quarter-over-quarter.
- 22 funds opened new Celldex Therapeutics positions in Q1 2023 and 26 closed out, a net change of -4 holders.
- The largest Celldex Therapeutics buyer in Q1 2023 was Pictet Asset Management (Switzerland), an estimated $33.6M added.
- The largest Celldex Therapeutics seller in Q1 2023 was Wellington Management Group, an estimated $20.1M sold.
Based on aggregated 13F filings for Q1 2023.